Qlife Holding AB ("Qlife" or the "Company") announces an extension of the Letter of Intent regarding a potential reverse takeover (the "Transaction") with Hipro Biotechnology Co., Ltd. ("Hipro"). The Transaction was announced by the Company through a press release on 5 June 2025. The term and exclusivity of the Letter of Intent have been extended, and the Transaction would be conditional upon, inter alia, the signing of a share purchase agreement no later than 31 December 2025. The other material terms and conditions of the Transaction as previously communicated by the Company remain unchanged.
The parties remain fully committed to the strategic rationale of the transaction and are aligned in their intent to execute it as outlined in the Letter of Intent.
For more information about the intended terms of the Transaction, please refer to the press release that was published on 5 June 2025 "Qlife Holding AB: Qlife enters letter of intent with Hipro Biotechnology Co., Ltd. to join forces through a reverse takeover".
For more information, please contact:
Thomas Warthoe, CEO
tw@egoo.health
+45 21 63 35 34
About Qlife
Qlife is a Swedish company based in Göteborg, which develops and markets an innovative medical technology platform, Egoo.Health ("Egoo"), with the goal of giving people access to clinical biomarker data when testing at home. The company is listed on the Nasdaq First North Growth Market (ticker: QLIFE). G&W Fondkommission is the Company's Certified Adviser. For additional information, please visit www.qlifeholding.com.
